Perception and acceptance of intradermal influenza vaccination: Patient reported outcomes from phase 3 clinical trials

Human Vaccines

Volumn 6, Issue 4, 2010, Pages 336-345

  Reygrobellet, Camille ^a   Viala Danten, Muriel ^b   Meunier, Juliette ^b   Weber, Françoise ^a   Nguyen, Van Hung ^a  

^a SANOFI PASTEUR   (France)

^b MAPI VALUES   (United States)

Author keywords

Acceptability; Influenza vaccine; Injection site reactions; Intradermal injection; Patient reported outcomes

Indexed keywords

INFLUENZA VACCINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DEMOGRAPHY; FEVER; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MICROINJECTION; MYALGIA; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; QUESTIONNAIRE; REVACCINATION; SHIVERING; SLEEP; STATISTICAL ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; EUROPE; FEMALE; HUMANS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; QUESTIONNAIRES; VACCINATION; YOUNG ADULT;

EID: 77953636988     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.4.10753     Document Type: Article

References (16)

1. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7:1201-14.
2. Workman B. Safe injection techniques. Nurs Stand 1999; 13:47-53.
3. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008; 26:3197-208.
4. Delore V, Salamand C, Marsh G, Arnoux S, Pepin S, Saliou P. Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip® . Vaccine 2006; 24:1586-92.
5. Holland D, Booy R, De Looze F, Eizenberg P, McDonald J, Karrasch J, et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008; 198:650-8.
6. Laurent PE, Bonnet S, Alchas P, Regolini P, Mikszta JA, Pettis R, et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 2007; 25:8833-42.
7. Leroux-Roels I, Vets E, Freese R, Seiberling M, Weber F, Salamand C, et al. Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults. Vaccine 2008; 26:6641-9.
8. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: The example of health-related quality of life: A European guidance document for the improved integration of healthrelated quality of life assessment in the drug regulatory process. Drug Inf J 2002; 36:209-38.
9. Chevat C, Viala-Danten M, Dias-Barbosa C, Nguyen VH. Development and psychometric validation of a self-administered questionnaire assessing the acceptance of influenza vaccination: the VAccinees' Perception of Injection (VAPI©) questionnaire. Health and Quality of Life Outcomes 2009; 7:21.
10. Spila-Alegiani S, Salmaso S, Rota MC, Tozzi AE, Raschetti R. Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination. Vaccine 1999; 17:1898-904.
11. Blank PR, Schwenkglenks M, Szucs TD. Disparities in Influenza Vaccination Coverage Rates by Target Group in Five European Countries: Trends Over Seven Consecutive Seasons. Infection 2009; [Epub ahead of print].
12. Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, van Hoecke C, et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004; 351:2286-94.
13. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-301.
14. Anonymous. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002; 11:193-205.
15. Arnou R, Ambrozaitis A, Eavis P, De Juanes Pardo JR, Kazek M-P, Weber F. Safety, immunogenicity and lot consistency of a novel intradermal influenza vaccine in young adults (aged <60 years): randomised controlled phase 3 trial results. Human Vaccine; In press.
16. Arnou R, Icardi G, De Decker M, Ambrozaitis A, Kazek MP, Weber F, Van Damme P. Intradermal influenza vaccine for older adults: A randomized controlled multicenter phase III study. Vaccine 2009; 27:7304-12.